Skip to content
Homepage
Author:
Larimar Therapeutics
Posted Date:
June 29, 2026
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
Larimar Therapeutics
June 29, 2026
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia
Larimar Therapeutics
June 26, 2026
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
Larimar Therapeutics
May 14, 2026
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
Larimar Therapeutics
April 30, 2026
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Larimar Therapeutics
March 19, 2026
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
Larimar Therapeutics
March 4, 2026
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
Larimar Therapeutics
February 25, 2026
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
Larimar Therapeutics
February 25, 2026
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026
Larimar Therapeutics
February 24, 2026
